Gilead Sciences Appoints Johanna Mercier as Chief Commercial Officer
May 29 2019 - 8:31AM
Business Wire
- Laura Hamill to Depart Gilead -
Gilead Sciences, Inc. (NASDAQ: GILD) today announced
that Johanna Mercier will join the company as Chief Commercial
Officer, and will become a member of the company’s senior
leadership team. Ms. Mercier will assume responsibility for the
company’s commercial operations effective July 1. Laura Hamill,
Executive Vice President Worldwide Commercial Operations, will be
departing from Gilead.
Ms. Mercier is a proven leader who brings to Gilead deep
experience in worldwide and senior operational roles in geographies
around the globe. She has held leadership positions in therapeutic
areas including oncology, inflammation and neuroscience. She joins
Gilead from Bristol-Myers Squibb, where she most recently served as
President and Head of the company’s Large Markets division, which
includes the United States, France, Germany and Japan. Over the
course of her career, she has helped drive growth across key
markets, pioneered innovative access strategies in the United
States and Europe and helped establish new standards of care for
people with cancer.
“I believe that Johanna has the skills to continue to strengthen
our performance and position Gilead for long-term success, building
on the great talent I have seen across the organization since
joining the company several months ago,” said Daniel O’Day,
Chairman and Chief Executive Officer. “She is a talented leader
with a deep understanding of the pharmaceutical industry, across
therapeutic markets and geographies, as well as a proven ability to
input the commercial perspective into development strategies. I
look forward to welcoming her to Gilead and to working closely with
her to ensure optimal commercial delivery that puts the needs of
patients at the center of all we do.”
In addition to her executive position at Bristol-Myers, Ms.
Mercier is a director on the Robert Wood Johnson University
Hospital Board. She holds a Master of Business Administration from
Concordia University and a Bachelor of Sciences in Biology from the
University of Montreal.
“Gilead is an organization that is deeply committed to bringing
forward transformational medicines for patients with serious
illnesses,” said Ms. Mercier. “Throughout my career, I have worked
to improve care for people with unmet medical needs and I am
excited to join a company that shares my commitment to doing what
is right for patients – and to advancing and commercializing
important new medicines.”
“During her time with Gilead, Laura has demonstrated a global
perspective, deep understanding of the industry and strong
commercial acumen,” commented Mr. O’Day. “I would like to
personally thank Laura for her commitment to Gilead as we work
through this period of transition and, on behalf of the company,
wish her the best in her future endeavors.”
About Gilead
Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical
company that discovers, develops and commercializes innovative
medicines in areas of unmet medical need. The company strives to
transform and simplify care for people with life-threatening
illnesses around the world. Gilead has operations in more than 35
countries worldwide, with headquarters in Foster City,
California.
For more information on Gilead Sciences,
please visit the company’s website at www.gilead.com, follow
Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190529005539/en/
Sung Lee, Investors650-524-7792
Marni Kottle, Media650-522-5388
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024